Industry supervisors envisage Japan to be the second fastest growing mature marketplace for solid dose drugs in 2019 followed by the United States. The findings represent a considerable year-on-year improvement in outlook for pharma in Japan with expected growth of solid dose formulations improving by more than 10% with generic drug classes highlighted Significantly, it ranks ahead of all EU nations and Korea. The report concludes that Japan is a ripened country for growth across a number of product classes, but the enduring winners of regulatory changes and innovative R&D remain hard to pick.
A recent study reveals that a highly pathogenic avian influenza (HPAI) outbreak killed over 330 New England harbor and gray seals along the North Atlantic coast in June and July 2022. This outbreak is associated with the wave of avian influenza in birds in the region. HPAI or bird flu is known to have spillover […]
According to new research published in the journal Immunity, neurons that produce the neurotransmitter dopamine communicate with T cells to intensify allergic inflammation in the lungs of young mice but not older mice. The findings rationalize that children are more susceptible to developing allergic asthma than adults. An estimated 6 million children have allergic asthma, […]
Donepezil, a drug that is commonly used in treating Alzheimer’s disease and many forms of dementia has been associated with increased risk of hospitalization for rhabdomyolysis, a painful condition of muscle breakdown. Rhabdomyolysis may also result in kidney-related diseases as well. Doctors suggest that the risk is low yet a statistically significant one. Reference Link: https://scitechdaily.com/commonly-used-drug-for-alzheimers-disease-doubles-risk-of-hospitalization/